Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.

Carlota Moya-AlarcónAlmudena González-DomínguezSusana SimonInés Pérez-RománAntonio González-MartínEloisa Bayo-LozanoAna Beatriz Sánchez-Heras

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.

Keyphrases

high grade
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
dna repair
squamous cell carcinoma
young adults
dna damage
patient reported